May 20, 2026 | Read online

Checking-in Early: See Why (HYFT) Just Popped On To Our Screen

Any content you receive is for information purposes only. Always conduct your own research.

*Sponsored

Daily Edge Report Initiates Coverage On MindWalk Holdings Corp. (NASDAQ: HYFT) Starting This Morning—Wednesday, May 20, 2026

Don’t miss the next breakout — get real-time alerts sent straight to your phone!

Full Coverage On (HYFT) Will Be Starting Now!

May 20, 2026

Checking-in Early: See Why (HYFT) Just Popped On To Our Screen

Dear Reader,

For years, much of the excitement around AI in dr-ug discovery has centered on teaching algorithms to recognize patterns in massive volumes of biological sequence data. But pattern recognition alone does not necessarily reveal how a molecule will function inside a living system.

MindWalk Holdings Corp. (NASDAQ: HYFT) is taking a fundamentally different approach.

Rather than focusing solely on sequence similarity, the company’s proprietary HYFT® technology is designed to analyze the functional building blocks of biology, the conserved subsequences that influence how proteins behave, interact, and perform specific tasks. In practical terms, (HYFT) is attempting to move beyond simply reading biology and toward understanding the rules that govern it.

That distinction may help explain why (HYFT) has begun attracting increasing attention.

In its third quarter of fiscal 2026, the company reported revenue growth of 52% year over year, while advancing three internal therapeutic programs, including a GLP-1 candidate that demonstrated stronger in vitro activity than semaglutide. At the same time, shares have gained approximately 40% since late March 2026, reaching $1.40 on May 11, according to Barchart.

According to TipRanks, two analysts currently maintain targets that imply roughly 300% upside potential from recent levels.

Technical indicators have also turned constructive. Barchart reports that (HYFT) is currently triggering multiple bullish signals, including the 20-day moving average, the 20/50-day moving average crossover, and the 50-day moving average.

When accelerating revenue growth, expanding pipeline progress, improving technical momentum, and bullish analyst targets begin to align, the result can be a story that commands closer attention.

That is why (HYFT) has moved to the top of our watchlist heading into Wednesday, May 20, 2026.

How (HYFT) Is Using AI to Accelerate the Future of Medicine

MindWalk Holdings Corp. (NASDAQ: HYFT) is a Bio-Native AI company focused on transforming how biologic dr-ugs are discovered and developed. Headquartered in Austin, Texas, the company combines proprietary artificial intelligence, multi-omics data, and integrated wet-lab capabilities to help pharmaceutical and biotechnology partners accelerate therapeutic development. MindWalk was formerly known as ImmunoPrecise Antibodies and rebranded in 2025 to reflect its expanded AI-driven platform strategy.

At the core of the company’s technology stack is its patented HYFT® (Hyperdimensional Functional Technology), which converts biological data into a unified computational language capable of analyzing sequence, structure, function, and scientific literature simultaneously. This foundation powers LensAI™, MindWalk’s flagship software platform designed to identify therapeutic targets, engineer antibodies, perform epitope mapping, and generate optimized biologic candidates more efficiently than traditional discovery methods.

(HYFT) offers its capabilities through several commercial models, including custom biologics discovery services, enterprise SaaS access to LensAI, strategic partnerships, and a portfolio of internally developed therapeutic assets. The company also operates a full-stack wet laboratory, enabling it to validate AI-generated insights experimentally and advance programs from computational design through preclinical development.

Beyond its technology platform, (HYFT) is advancing an internal pipeline targeting indications such as dengue, influenza, GLP-1–related metabolic applications, and neurodegenerative diseases. Through this combination of AI software, laboratory infrastructure, and proprietary therapeutic assets, MindWalk aims to reduce the cost, time, and uncertainty associated with bringing new biologic medicines to market.

The Multi-Bil-Dollar Market (HYFT) Is Built to Address

MindWalk Holdings Corp. (NASDAQ: HYFT) operates within the Healthcare sector, specifically the Biotechnology industry, but its strategic positioning extends into the rapidly expanding TechBio and AI-driven dr-ug discovery markets.

This emerging category combines artificial intelligence, large-scale biological data, and laboratory validation to improve how new therapies are identified and developed. Rather than functioning solely as a traditional biotech company, (HYFT) is building an integrated platform business that generates revenue through discovery services, enterprise software, strategic partnerships, and internally developed therapeutic assets.

The broader market potential is substantial. According to Global Market Insights, the global artificial intelligence in dr-ug discovery market is projected to grow from approximately $4.0B in 2026 to $43.9B by 2035, representing a compound annual growth rate of roughly 30.5%. Growth is being driven by pharmaceutical companies seeking to reduce the cost, risk, and time associated with developing new medicines.

(HYFT)’s commercial model aligns directly with several of the fastest-growing segments within this market:

AI-powered dr-ug discovery software
Biologics and antibody engineering
Nanobody and multispecific therapeutic design
Vaccine discovery
Enterprise SaaS licensing
Proprietary therapeutic development

The company’s HYFT® and LensAI™ platforms are designed to analyze sequence, structure, function, and scientific literature simultaneously, allowing researchers to identify targets and optimize molecules with greater precision. This approach positions (HYFT) to benefit from the growing convergence of software economics and biotechnology innovation.

From an analytical standpoint, (HYFT) offers exposure to multiple industry themes at once: the continued expansion of artificial intelligence, increasing adoption of computational biology, rising pharmaceutical outsourcing, and the growing demand for more efficient therapeutic development. As capital and strategic partnerships continue to flow into TechBio, companies with differentiated platforms and recurring software revenue models may attract increasing attention.

Recent Milestones Highlight (HYFT)’s Expanding AI dr-ug Discovery Platform

MindWalk Holdings Corp. (NASDAQ: HYFT) has released a series of updates in 2026 that underscore continued progress across its commercial platform, proprietary AI technology, and internal therapeutic pipeline.

First LensAI™ Enterprise Contract Signed: (HYFT) announced the signing of its first annual enterprise agreement for LensAI™, providing a pharmaceutical customer with ongoing access to the company’s AI-driven dr-ug discovery platform. This milestone is significant because it expands the company’s business model beyond project-based services and into recurring software revenue.

Third Quarter Fiscal 2026 Results Reported: The company reported 52% year-over-year revenue growth to approximately $4.2M, with U.S. revenue doubling to $2.6M. Management also highlighted progress in its dengue, influenza, and GLP-1 therapeutic programs and emphasized the growing contribution of its AI platform to commercial operations.

HYFT® Applied to Portfolio Risk Detection: (HYFT) introduced a new application of its HYFT® technology designed to detect “functional adjacency,” helping pharmaceutical companies identify molecules that may carry competitive or intellectual property risks despite having different sequences.

Breakthrough Discovery Targeting TDP-43: The company announced the discovery and validation of novel antibodies and intrabodies targeting pathogenic TDP-43, a protein linked to ALS, frontotemporal dementia, and other neurodegenerative disorders. The milestone demonstrated the potential of LensAI™ and HYFT® to identify highly specific therapeutic candidates in challenging disease areas.

Together, these milestones suggest that (HYFT) is gaining traction on several fronts simultaneously, including software commercialization, scientific validation, and proprietary therapeutic development.

7 Reasons (HYFT) Has Moved to the Top of Our Watchlist for Wednesday, May 20, 2026

1. Bullish Technical Setup: (HYFT) is currently triggering several positive technical indicators, including the 20-day moving average, the 20/50-day moving average crossover, and the 50-day moving average.

2. Strong Recent Action: (HYFT) have advanced approximately 40% since late March 2026, reaching $1.40 on May 11 based on Barchart historical data.

3. Analyst Targets Suggest Significant Upside: Two analysts have published targets implying roughly 300% upside potential from recent levels.

4. Revenue Growth Accelerating: In Q3 fiscal 2026, (HYFT) reported revenue of $4.2M CAD, up 52% from $2.7M CAD in the same quarter last year.

5. First Enterprise Software Contract Signed: The company’s largest in silico customer entered into a one-year enterprise agreement for LensAI™, adding a recurring monthly software revenue component to the business model.

6. Platform Validation in the Clinic: (HYFT)’s discovery engine has contributed to more than 21 partner-owned candidates and 10 active clinical programs spanning Phase 1 through Phase 3 studies.

7. Differentiated AI Technology: Through HYFT® and LensAI™, the company analyzes more than 25B biological relationships to identify functional patterns that may not be apparent through sequence-based methods alone.

Get (HYFT) On Your Radar This Morning…

When you combine 52% year-over-year revenue growth, the launch of recurring enterprise LensAI™ revenue, more than 21 partner-owned candidates, and 10 active clinical-stage programs, (HYFT) appears to be gaining traction across multiple areas of its business.

Add in a differentiated AI platform, analyst targets implying roughly 300% upside potential from recent levels, and a technical setup that continues to strengthen, and the story begins to stand out.

That is why (HYFT) has moved to the top of our watchlist heading this morning Wednesday, May 20, 2026.

We have all eyes on (HYFT) right now.

Take a look at (HYFT) this morning, while it’s still early.

Also, keep a look out for our next update—it could be here any moment.

Sincerely,

Joel Locke
Senior Editor
The Daily Edge Report

_{DailyEdgeReport.com}_{(“DailyEdgeReport” or “DER” ) is owned by GG Media Holdings LLC, a multi member limited liability company. Data is provided from third-party sources and DER is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile DER brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.}

_{Pursuant to an agreement between GG Media Holdings LLC and TD Media LLC, GG Media Holdings LLC has been hired for a period beginning on 05/19/2026 and ending on 05/20/2026 to publicly disseminate information about (HYFT:US) via digital communications. Under this agreement, TD Media LLC has paid GG Media Holdings LLC seven thousand five hundred USD (“Funds”). These Funds were part of the seventy five thousand USD funds that TD Media LLC received from a third party named Bergskogar Limit who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.}

_{Neither GG Media Holdings LLC, TD Media LLC and their member own shares of (HYFT:US).}

_{Please see important disclosure information here:}_{https://dailyedgereport.com/disclosure/hyft-j8Cgl/#details}